NPM1 and acute leukemia: In their recently published position statement paper, the acute leukemia working party of the EBMT recommended allogeneic HSCT in first CR for all FLT3-ITD mutated AML patients with the exception of NPM1 mutated/low FLT3-ITD allelic ratio individuals achieving an MRD-negative CR [30].